Progress in the study of negative symptoms

Schizophrenia Bulletin

Volumn 40, Issue SUPPL. 2, 2014, Pages

  Kirkpatrick, Brian ^a  

^a UNIVERSITY OF NEVADA SCHOOL OF MEDICINE   (United States)

Author keywords

Carpenter; deficit; factor analysis; festschrift; negative symptoms; nosology; randomized clinical trials

Indexed keywords

CYTOMEGALOVIRUS ANTIBODY; INTERLEUKIN 6;

ANHEDONIA; ANXIETY; ARTICLE; COGNITIVE DEFECT; DELUSION; DEPRESSION; DIFFUSION TENSOR IMAGING; DISEASE CLASSIFICATION; DISEASE DURATION; DISORIENTATION; DOUBLE DISSOCIATION; DYSKINESIA; EVENT RELATED POTENTIAL; EXTRAPYRAMIDAL SYMPTOM; GLUCOSE INTOLERANCE; GLUCOSE TOLERANCE; HALLUCINATION; HUMAN; META ANALYSIS (TOPIC); NEGATIVE SYNDROME; NEUROIMAGING; NONHUMAN; PHYSICAL DISEASE BY BODY FUNCTION; POSITIVE AND NEGATIVE SYNDROME SCALE; POSITIVE SYNDROME; PREFRONTAL CORTEX; PRIORITY JOURNAL; PSYCHOSIS; RISK FACTOR; SCHIZOPHRENIA; SEASONAL VARIATION; SOCIAL ISOLATION; STUDY DESIGN; SUMMER; SUSPICIOUSNESS; TREATMENT RESPONSE; WINTER; CLASSIFICATION; CLINICAL TRIAL (TOPIC); PATHOPHYSIOLOGY; STANDARDS;

CLINICAL TRIALS AS TOPIC; HUMANS; SCHIZOPHRENIA;

EID: 84895746518     PISSN: 05867614     EISSN: 17451701     Source Type: Journal    
DOI: 10.1093/schbul/sbt158     Document Type: Article

References (67)

1. Tek C, Kirkpatrick B, Buchanan RW. A five-year followup study of deficit and nondeficit schizophrenia. Schizophr Res. 2001;49:253-260.
2. Griesinger W. Mental Pathology and Therapeutics. 2nd ed. Robertson CL, Rutherford J, trans. London: New Sydenham Society; 1867.
3. Kraepelin E. Dementia Praecox and Paraphrenia. Melbourne, FL: Krieger (originally published in 1919); 1971.
4. Overall JE, Gorham DR. The Brief Psychiatric Rating Scale. Psycholog Rep. 1962;10:799-812.
5. Andreasen NC. Negative symptoms in schizophrenia. Definition and reliability. Arch Gen Psychiatry. 1982;39:784-788.
6. Strauss JS, Carpenter WT Jr, Bartko JJ. The diagnosis and understanding of schizophrenia. Part III. Speculations on the processes that underlie schizophrenic symptoms and signs. Schizophr Bull. 1974;11:61-69.
7. Buchanan RW, Carpenter WT. Domains of psychopathology: an approach to the reduction of heterogeneity in schizophrenia. J Nerv Ment Dis. 1994;182:193-204.
8. Kirkpatrick B, Ryan WG. A default analysis for schizophrenia research. Schizophr Bull. 2000;26:157-162.
9. Kirkpatrick B, Strauss GP, Nguyen L, et al. The brief negative symptom scale: psychometric properties. Schizophr Bull. 2011;37:300-305.
10. Strauss GP, Keller WR, Buchanan RW, et al. Next-generation negative symptom assessment for clinical trials: validation of the Brief Negative Symptom Scale. Schizophr Res. 2012;142:88-92.
11. Horan WP, Kring AM, Gur RE, Reise SP, Blanchard JJ. Development and psychometric validation of the Clinical Assessment Interview for Negative Symptoms (CAINS). Schizophr Res. 2011;132:140-145.
12. Kring AM, Gur RE, Blanchard JJ, Horan WP, Reise SP. The Clinical Assessment Interview for Negative Symptoms (CAINS): final development and validation. Am J Psychiatry. 2013;170:165-172.
13. Blanchard JJ, Cohen AS. The structure of negative symptoms within schizophrenia: implications for assessment. Schizophr Bull. 2006;32:238-245.
14. Kirkpatrick B, Buchanan RW, McKenney PD, Alphs LD, Carpenter WT Jr. The Schedule for the Deficit syndrome: an instrument for research in schizophrenia. Psychiatry Res. 1989;30:119-123.
15. Strauss GP, Hong LE, Gold JM, et al. Factor structure of the Brief Negative Symptom Scale. Schizophr Res. 2012;142:96-98.
16. Galderisi S, Bucci P, Mucci A, et al. Categorical and dimensional approaches to negative symptoms of schizophrenia: focus on long-term stability and functional outcome. Schizophr Res. 2013;147:157-162.
17. Nakaya M, Ohmori K. A two-factor structure for the Schedule for the Deficit Syndrome in schizophrenia. Psychiatry Res. 2008;158:256-259.
18. Kimhy D, Yale S, Goetz RR, McFarr LM, Malaspina D. The factorial structure of the schedule for the deficit syndrome in schizophrenia. Schizophr Bull. 2006;32:274-278.
19. Liemburg E, Castelein S, Stewart R, van der Gaag M, Aleman A, Knegtering H; Genetic Risk and Outcome of Psychosis (GROUP) Investigators. Two subdomains of negative symptoms in psychotic disorders: established and confirmed in two large cohorts. J Psychiatr Res. 2013;47:718-725.
20. Strauss GP, Horan WP, Kirkpatrick B, et al. Deconstructing negative symptoms of schizophrenia: avolition-apathy and diminished expression clusters predict clinical presentation and functional outcome. J Psychiatr Res. 2013;47:783-790.
21. Umbricht D, Lentz E, Lalonde J, Martin-Facklam M, Santarelli L. The effect of bitopertin, a glycine reuptake inhibitor, on key negative symptom dimensions and association with estimated GlyT1 occupancy [abstracts]. International Congress on Schizophrenia Research, 2013.
22. Carpenter WT Jr, Heinrichs DW, Wagman AM. Deficit and nondeficit forms of schizophrenia: the concept. Am J Psychiatry. 1988;145:578-583.
23. Kirkpatrick B, Buchanan RW, Ross DE, Carpenter WT Jr. A separate disease within the syndrome of schizophrenia. Arch Gen Psychiatry. 2001;58:165-171.
24. Fenton WS, McGlashan TH. Antecedents, symptom progression, and long-term outcome of the deficit syndrome in schizophrenia. Am J Psychiatry. 1994;151:351-356.
25. Amador XF, Kirkpatrick B, Buchanan RW, Carpenter WT, Marcinko L, Yale SA. Stability of the diagnosis of deficit syndrome in schizophrenia. Am J Psychiatry. 1999;156:637-639.
26. Kirkpatrick B, Galderisi S. Deficit schizophrenia: an update. World Psychiatry. 2008;7:143-147.
27. Arango C, Adami H, Sherr JD, Thaker GK, Carpenter WT Jr. Relationship of awareness of dyskinesia in schizophrenia to insight into mental illness. Am J Psychiatry. 1999;156:1097-1099.
28. Trotman HD, Kirkpatrick B, Compton MT. Impaired insight in patients with newly diagnosed nonaffective psychotic disorders with and without deficit features. Schizophr Res. 2011;126:252-256.
29. Kirkpatrick B, Buchanan RW, Breier A, Carpenter WT Jr. Case identification and stability of the deficit syndrome of schizophrenia. Psychiatry Res. 1993;47:47-56.
30. Kirkpatrick B, Amador XF, Yale SA, Bustillo JR, Buchanan RW, Tohen M. The deficit syndrome in the DSM-IV Field Trial. Part II. Depressive episodes and persecutory beliefs. Schizophr Res. 1996;20:79-90.
31. Fenton WS, Wyatt RJ, McGlashan TH. Risk factors for spontaneous dyskinesia in schizophrenia. Arch Gen Psychiatry. 1994;51:643-650.
32. Telfer S, Shivashankar S, Krishnadas R, McCreadie RG, Kirkpatrick B. Tardive dyskinesia and deficit schizophrenia. Acta Psychiatr Scand. 2011;124:357-362.
33. Buchanan RW, Kirkpatrick B, Heinrichs DW, Carpenter WT Jr. Clinical correlates of the deficit syndrome of schizophrenia. Am J Psychiatry. 1990;147:290-294.
34. Kirkpatrick B, Amador XF, Yale SA, Bustillo JR, Buchanan RW, Tohen M. The deficit syndrome in the DSM-IV Field Trial. Part II. Depressive episodes and persecutory beliefs. Schizophr Res. 1996;20:79-90.
35. Messias E, Kirkpatrick B, Bromet E, et al. Summer birth and deficit schizophrenia: a pooled analysis from 6 countries. Arch Gen Psychiatry. 2004;61:985-989.
36. Welham J, Chant D, Saha S, McGrath J, Kirkpatrick B, Castle D. No association between the deficit syndrome in psychosis and summer birth in a Southern hemisphere country. Aust N Z J Psychiatry. 2006;40:935-936.
37. Kirkpatrick B, Castle D, Murray RM, Carpenter WT Jr. Risk factors for the deficit syndrome of schizophrenia. Schizophr Bull. 2000;26:233-242.
38. Kirkpatrick B, Ross DE, Walsh D, Karkowski L, Kendler KS. Family characteristics of deficit and nondeficit schizophrenia in the Roscommon Family Study. Schizophr Res. 2000;45:57-64.
39. Ross DE, Kirkpatrick B, Karkowski LM, et al. Sibling correlation of deficit syndrome in the Irish study of high-density schizophrenia families. Am J Psychiatry. 2000;157:1071-1076.
40. Dickerson F, Kirkpatrick B, Boronow J, Stallings C, Origoni A, Yolken R. Deficit schizophrenia: association with serum antibodies to cytomegalovirus. Schizophr Bull. 2006;32:396-400.
41. Arango C, McMahon RP, Lefkowitz DM, Pearlson G, Kirkpatrick B, Buchanan RW. Patterns of cranial, brain and sulcal CSF volumes in male and female deficit and nondeficit patients with schizophrenia. Psychiatry Res. 2008;162:91-100.
42. Fischer BA, Keller WR, Arango C, et al. Cortical structural abnormalities in deficit versus nondeficit schizophrenia. Schizophr Res. 2012;136:51-54.
43. Voineskos AN, Foussias G, Lerch J, et al. Neuroimaging evidence for the deficit subtype of schizophrenia. JAMA Psychiatry. 2013;70:472-480.
44. Tamminga CA, Thaker GK, Buchanan R, et al. Limbic system abnormalities identified in schizophrenia using positron emission tomography with fluorodeoxyglucose and neocortical alterations with deficit syndrome. Arch Gen Psychiatry. 1992;49:522-530.
45. Fernandez-Egea E, Parelada E, Sugranyes G, et al. Left amygdalar activation in deficit syndrome compared with nondeficit subjects with schizophrenia during the control task in a facial emotion recognition paradigm. Psychiatry Res. 2012;203:109-110.
46. Heckers S, Goff D, Schacter DL, et al. Functional imaging of memory retrieval in deficit vs nondeficit schizophrenia. Arch Gen Psychiatry. 1999;56:1117-1123.
47. Delamillieure P, Fernandez J, Constans JM, et al. Proton magnetic resonance spectroscopy of the medial prefrontal cortex in patients with deficit schizophrenia: preliminary report. Am J Psychiatry. 2000;157:641-643.
48. Delamillieure P, Constans JM, Fernandez J, Brazo P, Dollfus S. Relationship between performance on the Stroop test and N-acetylaspartate in the medial prefrontal cortex in deficit and nondeficit schizophrenia: preliminary results. Psychiatry Res. 2004;132:87-89.
49. Kirkpatrick B, Fernandez-Egea E, Garcia-Rizo C, Bernardo M. Differences in glucose tolerance between deficit and nondeficit schizophrenia. Schizophr Res. 2009;107:122-127.
50. Garcia-Rizo C, Fernandez-Egea E, Oliveira C, Justicia A, Bernardo M, Kirkpatrick B. Inflammatory markers in antipsychotic-naïve patients with nonaffective psychosis and deficit vs. nondeficit features. Schizophr Res. 2012;134:16-19.
51. Cohen AS, Saperstein AM, Gold JM, Kirkpatrick B, Carpenter WT Jr, Buchanan RW. Neuropsychology of the deficit syndrome: new data and meta-analysis of findings to date. Schizophr Bull. 2007;33:1201-1212.
52. Buchanan RW, Strauss ME, Breier A, Kirkpatrick B, Carpenter WT Jr. Attentional impairments in deficit and nondeficit forms of schizophrenia. Am J Psychiatry. 1997;154:363-370.
53. Mucci A, Galderisi S, Kirkpatrick B, et al. Double dissociation of N1 and P3 abnormalities in deficit and nondeficit schizophrenia. Schizophr Res. 2007;92:252-261.
54. Santos JL, Sánchez-Morla EM, Aparicio A, et al. P50 gating in deficit and nondeficit schizophrenia. Schizophr Res. 2010;119:183-190.
55. Seckinger RA, Goudsmit N, Coleman E, et al. Olfactory identification and WAIS-R performance in deficit and nondeficit schizophrenia. Schizophr Res. 2004;69:55-65.
56. Goudsmit N, Coleman E, Seckinger RA, et al. A brief smell identification test discriminates between deficit and non-deficit schizophrenia. Psychiatry Res. 2003;120:155-164.
57. Malaspina D, Coleman E, Goetz RR, et al. Odor identification, eye tracking and deficit syndrome schizophrenia. Biol Psychiatry. 2002;51:809-815.
58. Strauss GP, Allen DN, Ross SA, Duke LA, Schwartz J. Olfactory hedonic judgment in patients with deficit syndrome schizophrenia. Schizophr Bull. 2010;36:860-868.
59. Arango C, Kirkpatrick B, Buchanan RW. Neurological signs and the heterogeneity of schizophrenia. Am J Psychiatry. 2000;157:560-565.
60. Kopelowicz A, Liberman RP, Mintz J, Zarate R. Comparison of efficacy of social skills training for deficit and nondeficit negative symptoms in schizophrenia. Am J Psychiatry. 1997;154:424-425.
61. Kopelowicz A, Zarate R, Tripodis K, Gonzalez V, Mintz J. Differential efficacy of olanzapine for deficit and nondeficit negative symptoms in schizophrenia. Am J Psychiatry. 2000;157:987-993.
62. Kirkpatrick B, Conley RC, Kakoyannis A, Reep RL, Roberts RC. Interstitial cells of the white matter in the inferior parietal cortex in schizophrenia: An unbiased cell-counting study. Synapse. 1999;34:95-102.
63. Kirkpatrick B, Messias NC, Conley RR, Roberts RC. Interstitial cells of the white matter in the dorsolateral prefrontal cortex in deficit and nondeficit schizophrenia. J Nerv Ment Dis. 2003;191:563-567.
64. Kirkpatrick B, Kopelowicz A, Buchanan RW, Carpenter WT Jr. Assessing the efficacy of treatments for the deficit syndrome of schizophrenia. Neuropsychopharmacology. 2000;22:303-310.
65. Kirkpatrick B, Fenton WS, Carpenter WT Jr, Marder SR. The NIMH-MATRICS consensus statement on negative symptoms. Schizophr Bull. 2006;32:214-219.
66. Buchanan RW, Javitt DC, Marder SR, et al. The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): the efficacy of glutamatergic agents for negative symptoms and cognitive impairments. Am J Psychiatry. 2007;164:1593-1602.
67. Freedman R, Olincy A, Buchanan RW, et al. Initial phase 2 trial of a nicotinic agonist in schizophrenia. Am J Psychiatry. 2008;165:1040-1047.